Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677704 | 1.00 | AAK1 (0.36) | AAK1TRPA1NPC1SLC22A12PTGDR2 | |
| SCHEMBL5679771 | 0.92 | SLC22A12 (0.38) | AAK1SLC22A12PTGDR2LMNAKMO | |
| SCHEMBL5679765 | 0.92 | SLC22A12 (0.38) | AAK1SLC22A12PTGDR2LMNAKMO | |
| SCHEMBL5678047 | 0.83 | GLS (0.43) | NPC1LMNACTSSCTSK | |
| SCHEMBL5679657 | 0.83 | DYRK1A (0.46) | SLC22A12 | |
| SCHEMBL5679666 | 0.83 | DYRK1A (0.46) | SLC22A12 | |
| SCHEMBL5678084 | 0.77 | BRD4 (0.37) | AAK1SLC22A12LMNACTSSCTSK | |
| SCHEMBL5678090 | 0.77 | BRD4 (0.37) | AAK1SLC22A12LMNACTSSCTSK | |
| SCHEMBL5679751 | 0.73 | AAK1 (0.41) | AAK1SLC22A12CTSSCTSK | |
| SCHEMBL5679757 | 0.73 | AAK1 (0.41) | AAK1SLC22A12CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129078-B1 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RES LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |